VRTX - Vertex Pharmaceuticals Inc - Page 2
Vertex's Eyes Upcoming PDUFA/NDA for Incivek
Vertex Pharmaceuticals, a pharmaceutical company focused on small molecule drugs targeting a number of diseases, could see near-term upside upon PDUFA approval of its Incivek NDA on May 23, 2011. Meanwhile, the company also benefited from the recent FDA approval of telaprevir for people with genotype 1 chronic hepatitis C.
Goldman Sachs is very bullish on the stock – and particularly the near-term call options – saying that they may make the company a more attractive M&A target. The analyst issued a $59.00 per share price target, but noted upside that could approach $87.00 in the event of an acquisition. Meanwhile, similar sentiments were echoed by ThinkEquity, which maintains a $62.00 per share price target.
Source: SA article by Monger